Chronic myelogenous leukemia (CML) is characterized by the
Introduction
Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myelogenous leukemia (CML) and is found in up to 95% of CML patients. 1 The demonstration of bcr/abl mRNA is accepted as a reliable diagnostic marker for CML, and in some cases this evidence is more reliable than the Ph chromosome. 2 The clinical signs and hematological findings probably depend partly on the presence of P210 BCR/ABL , which plays a central role in the pathogenesis of the chronic phase of CML.
patients, there are two bcr/abl mRNAs for P210 BCR/ABL , one with and one without exon b3 (b3-a2 type and b2-a2 type). 4 In a smaller number of CML patients, there are two other types of bcr/abl mRNAs based on the breakpoint positions of the bcr gene, ie m-bcr and -bcr for P190
BCR/ABL and P230 BCR/ABL , respectively. 5, 6 Extensive studies have been performed on the subtypes of the bcr/abl gene and their relation to the prognosis and clinical features. 7, 8 The established findings regarding the influence of the subtype of the bcr/abl gene (b3-a2 or b2-a2) on the clinical characteristics have been similar for each subtype, except for a higher platelet count in patients with the b3-a2 type. 4, 9 P190 BCR/ABL in CML may be associated with monocytosis, and P230 BCR/ABL may be associated with the chronic neutrophilic leukemia variant and marked thrombocytosis. 6, 10 Other molecular factors which might control the clinical features and hematological characteristics remain unclear.
Recently, the stem cell factor (SCF) c-kit signal system (KIT/SCF) has been shown to play a crucial role in hematopoiesis. 11 The c-kit receptor tyrosine kinase (KIT) is expressed on progenitor stem cells as well as mast cells. SCF synergizes in vitro with other cytokines to increase the number and size of colonies of hematopoietic progenitors. 12 Thus, we speculated that the KIT/SCF system possibly controls the hematological characteristics of CML.
The present study was designed to investigate the mutations of the c-kit gene and the relationship between the in vitro function of mutant c-kit and the biological features of CML patients.
Materials and methods

Patients
We studied 116 bone marrow (BM) or peripheral blood (PB) samples obtained from 80 patients with CML in various clinical phases: 65 in chronic phase (CP), seven in accelerated phase (AP), and 44 in blastic crisis (BC). The diagnosis of CML was made on the basis of clinical features, hematological data and Ph chromosome. In 34 patients, both cytogenetic and molecular analyses were performed in more than two phases, ie CP and BC (30 patients), CP and AP (two patients), and CP, AP and BC (two patients). Sixty-eight normal BM or PB samples were obtained to study mutation and polymorphism of the c-kit gene. These samples were obtained with the patients' and normal volunteers' informed consent.
Cells
Ba/F3, 13 a murine IL-3-dependent pro-B lymphoid cell line, was cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and 10% WEHI-3 cell conditioned medium.
Extraction of RNA and DNA
The total RNA of BM or PB leukocytes was extracted with an RNAzol kit (Biotex Laboratories, Houston, TX, USA), which was based on a technique described previously. 14 The total cellular DNA was extracted from BM and PB cells by protease K digestion, phenol-chloroform extraction and ethanol precipitation.
RT-PCR of c-kit mRNA
RT-PCR was performed as described elsewhere. 15 The sense primers were: kit560-1, 5Ј-CTGTTCACTCCTTTGCTGAT-3Ј (residues 1582-1601); kit560-2, 5Ј-TTCGTAATCGT AGCTGGCAT-3Ј (residues 1605-1624); kit816-1, 5Ј-ATCATGGAGGATGACGAGTTG-3Ј (residues 2287-2306); and kit816-2, 5Ј-CTAGACTTAGAAGACTTGCT-3Ј (residues 2310-2329). The antisense primers were: kit560-3, 5Ј-CATGTGATTACCAAGGTAA-3Ј
(residues 1955-1974); kit560-4, 5Ј-GCTCCAAGTAGATTCACAAT-3Ј (residues 1978-1997); kit816-3, 5Ј-ATTTCAGCAGGTGCGTGTTC-3Ј (residues 2698-2717); and kit816-4, 5Ј-TTTTTA GGGGATCTGCATCC-3Ј (residues 2742-2761). Complementary DNA was synthesized from 500 ng of total cellular RNA extracted from cells using 100 ng of primer kit560-4 for analysis of the sequence in the juxtamembrane domain or kit816-4 for analysis of the phosphotransferase domain. Briefly, RT reaction mixture contained 32 U of avian myeloblastosis virus (AMV) RT (Takara Biochemicals, Shiga, Japan) in 25 l of a solution containing 200 mol/l each of all four dNTPs, 80 U of RNase inhibitor, 50 mmol/l Tris-HCl (pH 8.3), 75 mmol/l KCl, 10 mmol/l dithiothreitol and 3 mmol/l MgCl 2 . The reaction was allowed to proceed for 60 min at 37°C, and the reaction mixture was used as the PCR substrate. A 35-cycle PCR reaction was performed in a DNA Thermal Cycler with slight modification of our original protocol. 4 Briefly, 25 l of the RT reaction solution was mixed with a mixture containing 250 mol/l of each of all four dNTPs, 100 ng of 5Ј-primer ST1, 10 mmol/l Tris-HCl (pH 8.3) , 50 mmol/l KCl, 3 U of Taq DNA polymerase (Takara Biochemicals) and 100 ng of primers kit560-1 and kit560-4 or primers kit816-1 and kit816-4. The reaction conditions and cycle number were the same as those described above. A second PCR was performed for direct sequencing. Primers kit560-2 and kit560-3 or primers kit816-2 and kit816-3 were used to amplify the first PCR products, whereas primers SC3 and ASC3 were used for the 3Ј-fragment.
Single-stranded conformation polymorphism (SSCP) gel analysis
Detection of c-kit mutations was performed by SSCP gel analysis. The 5Ј-ends of primers (100 pmol) were labeled with ␥-32 P-ATP (3000 Ci/mmol) and polynucleotide (5 U, Boehringer-Mannheim; Mannheim, Germany) in 10 l of 50 mM Tris-HCl, pH 8.3, 10 mM MgCl 2 and 5 mM DTT at 37°C for 30 min. The PCR mixture contained 10 pmol of each of the labeled primers, 2 nmol each of the four deoxynucleotides, 0.1 g of sample cDNA or DNA, and 0.25 U of Taq polymerase in 10 l of the buffer provided in the GeneAmp kit. The PCR products were mixed with 10 volumes of a loading buffer containing 95% formamide, 20 mM EDTA, 0.05% bromphenol blue and 0.05% xylene cyanol, denatured at 94°C for 5 min, quenched on ice and applied (1 l/lane) to Leukemia a 10% polyacrylamide gel containing 90 mM Tris-borate, pH 8.3, 4 mM EDTA, and 10% glycerol. Electrophoresis was performed at 40 W for 3 h at 18°with cooling using a water jacket. The gel was dried on a filter paper and exposed to X-ray film at −80°for 1-24 h with an intensifying screen.
Sequence analysis of the c-kit gene
After the RT-PCR products were separated on 2% agarose gels and stained with ethidium bromide, the amplified fragment was excised from the gel, electroeluted, purified with phenol and precipitated with ethanol. The fragments were subcloned into the EcoRV site of the pGEM-5Zf(+/−) cloning vector. 16 The transfected cells were plated on to Luria-Beriani (LB)-ampicillin agar plates containing 5-bromo-4-chloro-3-indolyl-␤-Dgalactoside (X-Gal), isotransferred to fresh LB-ampicillin agar plates containing X-Gal and isopropylthio-␤-D-galactoside, and cultured overnight for secondary selection. White colonies were transferred into 150 ml of LB medium containing 50 mg/ml ampicillin and cultured at 37°C for 4 h. The cultures were sedimented by centrifugation, resuspended in 20 ml of water and heated at 98°C for 10 min. After centrifugation, the supernatants were amplified by PCR using the T7 or SP6 primer. Three to five clones of the three independent PCR products were sequenced using a Model 377 ABI sequencer with dye terminators (Perkin Elmer, Warrington, UK). All sequences were confirmed in both orientations. A mutation was defined as when three or more clones showed the same abnormality of the base sequence.
Site-directed mutagenesis and transfection
To examine for functional abnormality of c-kit mutations in activation of c-kit tyrosine kinase activity, site-directed mutagenesis was performed using murine c-kit cDNA as described by Furitsu et al. 17 The genes encoding murine wildtype c-kit and c-kit c-DNA with a mutation at codon 814 (GAC→GTC) in the XbaI site of the expression vector, pEF-BOS, were used as wild and mutant controls. 18 These two ckit expression vectors were kindly provided by Prof Y Kanakura (Osaka University, Osaka, Japan). To generate genes containing L-540, two oligonucleotide sets of 5Ј-GCAT-TATTGTGCTGATTCTGACCTACAAAT-3Ј and 3Ј-CAGAA TCAGCACAATAATGCACATCATGCC-5Ј were synthesized, annealed to the template and extended. To generate genes containing K-563, two oligonucleotide sets of 5Ј-GAGGAGA TAAGTGGAAACAATTATGTTTAC-3Ј and 3Ј-ATTGTTTCC ACTTATCTCCTCAACAACCTTCC A-5Ј were synthesized, annealed to the template and extended, according to the instructions accompanying the ExSite PCR-Based SiteDirected Mutagenesis kit (Stratagene, La Jolla, CA, USA). Fifteen temperature-cycles of PCR were performed to extend and incorporate mutation primers by Pfu Turbo DNA polymerase, resulting in formation of mutated circular strands. Methylated parental DNA template was digested with 10 U of DpI. The mutated double-stranded plasmid was transformed into XL1-Blue E. coli cells to expand the plasmid after repairing the nicks with T4 DNA ligase. The c-kit cDNA and expression vectors were sequenced to confirm the mutations and absence of artifact abnormalities.
The expression vectors containing wild-type and mutated ckit cDNA (10 g) were transfected by electroporation into 5 × 10
7 Ba/F3 cells with pSV2Neo (0.2 g), which encodes and expresses the neomycin-resistant protein. The Ba/F3 cells were cultured in RPMI 1640 containing 10% FCS 600 g/ml G418 (Calbiochem-Novabiochem, San Diego, CA, USA) and 10% WEHI-3 cell-conditioned medium. After selection with G418 and limiting dilution of the cells, expression of KIT was confirmed by flow cytometry.
Flow cytometry
To detect cell surface expression of KIT, cells were incubated with fluorescein isothiocyanate (FITC)-conjugated anti-KIT (2B8 clone; PharMingen, San Diego, CA, USA) MoAb at 4°C for 30 min and analyzed on a FACScan (Becton Dickinson, Los Angeles, CA, USA). 15 
Immune complex kinase assay
The procedures of immunoprecipitation, gel electrophoresis and immunoblotting were performed according to the methods described previously. 19 The cells were washed with PBS and lysed in 500 l of RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.5% deoxycholate, and 0.1% SDS with protease inhibitors (1 mM PMSF, 50 g/ml of antipain, 5 g/ml of aprotinin, and 2 g/ml of leupeptin)). Cell debris was removed by centrifugation. The supernatant was precleared by incubation with protein-G Sepharose (Pharmacia, Uppsala, Sweden) on ice for 30 min. The precleared lysates were incubated with anti-mouse c-kit MoAb, 2B8 (PharMingen) for 1 h on ice and with Protein-G Sepharose for 30 min on ice to collect antigen-antibody complexes. The immunoprecipitates were washed three times with NP-40 buffer (50 mM Tris, pH 8.0, 1.0% NP-40, 50 mM NaCl) containing protease inhibitors. The proteins released from the immunoprecipitates by Laemli's sample buffer were subsequently analyzed by electrophoresis on 5-25% SDS-PAGE. The proteins were electrophoretically transferred from the gel on to a nitrocellulose membrane. After the transfer, the filter was blocked by incubation in 1% BSA/Tween-PBS (1.37 M NaCl, 27 mM KCl, 81 mM Na 2 HPO 4 , 15 mM KH 2 PO 4 , 1% Tween-20, 1% BSA). Immunoblotting was performed with an antiphosphotyrosine MoAb (Py20; PharMingen) or anti-c-kit antibody, and detected with HRP-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). All immunoprecipitates were detected with HPR-conjugated goat anti-mouse IgG and visualized by autoradiography.
Semiquantification of the photographic signals was performed using an MCID image analysis system (Imaging Research, St Catherines, Ontario, Canada). The entire width of the lane was analyzed with appropriate background subtraction. All bands in one photograph were analyzed together. The relative intensity was defined as the ratio of the KIT phosphorylation signals to KIT V814 signals at 15 min incubation.
Cell proliferation assay
Proliferation of cells was quantified by 
Determination of the type of bcr/abl mRNA
Reverse transcriptase-polymerase chain reaction analysis (RT-PCR) for determination of the type of bcr/abl mRNA was carried out as described previously. 4, 16 Briefly, complementary DNA (cDNA) was prepared from 250 ng of total RNA using an antisense ABL cDNA primer. Primers bcr-1 and abl-1 were used for PCR for p210 mRNA, whereas primers e-1 and abl-1 were used for p190 mRNA. The PCR products were electrophoresed through a 2.5% agarose gel, stained with ethidium bromide, Southern-transferred and hybridized. Numbers were those at diagnosis of CP.
CP, chronic phase; BC, blastic crisis; HR, hair root; ND, not done; IFN, interferon-␣; HU, hydroxyurea; VP, combined therapy with vincristine and prednisolone.
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Statistical analysis
Statistical analysis was performed using the Statview (Brain Power, Calabashes, CA, USA) software package for the Macintosh personal computer. Comparisons of groups were analyzed using Fisher's exact test for 2 × 2 tables. Values of P Ͻ 0.05 were considered significant.
Results
c-kit mutations in CML patients
Eighty CML cases were screened for mutations in the coding region of the c-kit gene by RT-PCR-SSCP. Expression of the ckit gene was detected in all 80 CML patients by RT-PCR. Seven cases showed aberrant bands on RT-PCR-SSCP gels. Sequencing of the RT-PCR fragments which showed aberrant bands on the RT-PCR-SSCP gels revealed one of the seven cases had an abnormality at codon 564 (AAT→AAG, Asn→Lys) in the juxtamembrane domain, while six cases had an abnormality at codon 541 (ATG→CTG, Met→Leu) ( Figure  1 ). These two base abnormalities were observed in cDNA clones generated from three independent PCR products. Sixtyeight normal BM aspirate samples were obtained from hematologically healthy volunteers after obtaining informed consent and used as normal controls. One of the 68 healthy normal BM samples had the same migration pattern by SSCP and the same alteration as that of our CML patients at codon 541 in which ATG was changed to CTG, resulting in a change in the encoded amino acid from Met to Leu (Table 1) . The same codon 541 abnormality was detected in RNA samples from skin and hair roots of cases 3, 4, 5 and 6 ( Table 2) . Because the amino acid substitution was a conservative one which was also observed in the normal population and normal tissues of the CML patients, it probably represents a polymorphic variation. Intriguingly, however, RNA samples from the hair roots and leukemic cells at CP of case 2 were demonstrated to have no abnormality, whereas this case showed the same abnormality at codon 541 (ATG→CTG, Met→Leu) in the leukemic cells at BC. Thus, we think the alteration of codon 541, in which ATG was changed to CTG, occurred during leukemic progression of case 2. In case 1, the abnormality at codon 564 was detected only in an RNA sample from leukemic cells at BC (Figure 1 ).
c-kit receptor tyrosine kinase
In order to determine the functional role of c-kit abnormalities in ligand-independent activation of c-kit products, expression vectors containing normal or mutated murine c-kit genes were transfected into a murine IL-3-dependent cell line, Ba/F3 cells.
We used site-directed mutagenesis to construct two mutant murine c-kitR expression vectors: c-kit K563 coding for substitution of Lys for Asn at codon 563, and c-kit L540 coding for substitution of Leu for Met at codon 540, which correspond to Lys-564 and Leu-541 of abnormal human c-kitR, respectively. These murine c-kit-expression vectors were co-transfected into the Ba/F3 murine IL-3-dependent cell line with pSV 2 Neo, which contains the neomycin resistance gene, by electroporation. As a negative control, the pEF-BOS vector, without the c-kit gene, was transfected into Ba/F3 cells. After selection in a G418-containing medium for 2 weeks, surface expression of KIT on the transfected cells was examined with DX2, an anti-mouse c-kit MoAb. K563 or KIT
State of tyrosine phosphorylation of KIT
L540
To examine the state of KIT-tyrosyl phosphorylation in the transfected Ba/F3 cells, the cells were deprived of serum and growth factors for 12 h and then stimulated with 0.1, 1 or 100 ng/ml of rmSCF for 15 min. KIT was then immunoprecipitated and assayed by immunoblotting with either antiphosphotyrosine MoAb or anti-c-kit MoAb. As shown in Figure 2b , when wild-type or mutated c-kit genes were transfected into Ba/F3, the c-kit gene products were synthesized in the cells as 145-and 125-kDa proteins, respectively. Immunoblotting with an antiphosphotyrosine MoAb showed that increased phosphotyrosine was observed in KIT V814 regardless of rmSCF stimulation. In contrast, KIT WT , KIT L540 and KIT K563 were dosedependently phosphorylated on tyrosine after treatment with increasing concentrations of rmSCF. KIT L540 and KIT K563 were found to be more phosphorylated on tyrosine than KIT WT at 0.1 and 1.0 ng/ml of rmSCF (Figure 2) .
Repeated semi-quantification of immunoblots (Figure 3a ) and the time course for the induction using a narrower range of concentrations between 0 and 1.0 ng/ml of rmSCF ( Figure  3b) showed relatively higher efficiency than KIT WT between 0.1 and 1.0 ng/ml of rmSCF (Figure 3) . K563 were cultured in the presence of 0 to 100 ng/ml of rmIL-3 or 0 to 1000 ng/ml of rmSCF for 72 h, followed by measurement of cell proliferation using 3 H-thymidine uptake assay (Figure 4) . It was demonstrated that rmIL-3 induced dose-dependent proliferation whereas rmSCF induced no proliferation in the parental Ba/F3 or pEF-BOStransfected Ba/F3 cells. In addition to the proliferative response to rmIL-3, Ba/F3 cells expressing KIT WT , KIT K563 and KIT L540 induced dose-dependent proliferation in response to rmSCF over the range of 0.1 to 1000 ng/ml, indicating functional expression of KIT WT , KIT K563 and KIT
. KIT K563 induced a higher proliferative response to 0, 0.1 and 1 ng/ml of rmSCF than KIT WT . The proliferative response to 0.1 ng/ml of rmSCF by Ba/F3 cells expressing KIT L540 was relatively higher than the response by cells expressing KIT
WT . In contrast, Ba/F3 cells expressing KIT V814 proliferated even in the absence of both rmIL-3 and rmSCF. Table 2 shows the relationships between the clinical data and the molecular characteristics of the seven CML cases with a c-kit abnormality. Three kinds of bcr/abl junctions, ie the b2-a2 and b3-a2 types of major bcr breakpoint, and the minor bcr/abl type of minor bcr breakpoint, are shown in Table 2 . One of the seven CML cases with c-kit gene alterations had the b2-a2 type, while four had the b3-a2 type. Intriguingly, two CML patients with a c-kit abnormality had the rare, minor bcr/abl type. Case 6 had extramedullary onset, and case 7 had received 5-FU medication for several years for esophageal cancer. As shown in Table 2 , the platelet counts of all seven cases at diagnosis of CP were within or below the normal range, regardless of the type of bcr/abl junction. The platelet counts of CML with 564
Clinical features of CML patients with c-kit abnormality
Lys-, 541
Leu-KIT were marginally lower (P Ͻ 0.07, Table 3 ) than the counts of CML with wild-type KIT ( WT-KIT). The WBC count at diagnosis of six mutated cases was markedly higher than the other 73 cases of CML with KIT WT (P Ͻ 0.05, Table 3 ). The WBC count was relatively low in case 2 with a normal c-kit gene in CP. The mean survival duration of the seven CML patients with 564
Lys-or 541
Leu-KIT was 45.9 months, while that of the CML patients without any KIT abnormality was 69.6 months (Table 3) . 564
Lys-
KIT and 541
Leu-KIT may be prognostic factors (P Ͻ 0.04), as shown in Table 3 .
Discussion
The interstitial cells of Cajal (ICCs) and hematopoietic stem cells express both KIT and CD34. Gastrointestinal stromal tumors (GISTs) may originate from the ICCs. 20 CML may originate from hematopoietic stem cells that are double-positive for KIT and CD34. High expression of c-kit has been demonstrated on CD34
+ cells from chronic-phase CML patients. 20 Here, we successfully demonstrated that the juxtamembrane domain mutant occurs in some CML cells which are doublepositive for KIT and CD34 as well as in ICCs. The juxtamembrane domain mutant is found in GISTs. 21 The juxtamembrane domain mutant is also found in mast cell leukemia. 22 The tyrosine kinase domain mutant occurs only in human and murine mast cell leukemia, but the mechanism of tumorigenesis differs between the juxtamembrane domain mutant and the tyrosine kinase domain mutant. The former, the juxtamembrane domain mutant, is constitutively dimerized and activated without binding SCF, whereas the latter, the tyrosine kinase domain mutant, is constitutively activated without forming dimers. 23 In GISTs, mutations are located within an 11-amino acid stretch (Lys-550 to Val-560). 21 The tyrosine kinase and proliferation of Ba/F3 cells expressing these mutated KIT proteins were constitutively activated without SCF. 21 Another report shows two major types of deletion mutations involving codons 550-565 and codons 566-580, stretches which were especially common in GISTs. 22 In murine mastocytoma cells, the mutation is deletion of a 7-amino acid stretch (Thr-573 to His-579). 24 Point mutations/polymorphism at codon 564 or 541 is within or near these stretches involved in GIST mutations and deletion mutations of murine mastocytoma, although these mutations resulted in these mutant KITs not being constitutively activated. These in vitro biological differences may be partly due to differences in the mutation type, such as deletions of many nucleotides or one nucleotide mutation.
The 541
Leu-KIT mutation may be one of polymorphism, since it is found even in normal healthy people. In our CML patients, however, the frequency of the 541 Leu- KIT polymorphism was relatively more common compared with in normal individuals ( Table 1) . This higher frequency in CML was partly due to a newly occurring mutation at BC, such as in case 2.
The Ba/F3-cell proliferation-inducing activity of KIT L540 was the same as that of KIT WT . Tyrosine kinase activation of KIT L540 was slightly higher than that of KIT WT in medium containing 0.1 ng/ml of SCF. The tyrosine kinase activation and Ba/F3-cell proliferation activities of KIT K563 were relatively higher than those of wild-type KIT in medium containing between 0.1 and 1.0 ng/ml of SCF. Based on these in vitro data on tyrosine kinase activation and proliferation activities, KIT L540 and KIT K563 do not have exactly the same function as KIT WT . Unlike KIT WT , KIT L540 and KIT K563 may cause very low levels of spontaneous tyrosine kinase activation and cell proliferation even without SCF, as shown in Figures 3 and 4 . These findings may indicate that 541 Leu- KIT does not fall within the category of polymorphism. This is because the KIT abnormality of these cases was more common (8.8%) than in the normal healthy cases (1.5%; P Ͻ 0.05).
We speculate that these tiny differences in in vitro function may influence the clinical phenotype of CML. Recently, an internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene in acute myeloid leukemia patients was found to lead to leukocytosis and shorter survival. 25 The KIT and FLT3 proteins are members of the class III receptor tyrosine kinase family. 26 The ITD mutant of FLT3 is constitutively dimerized and autophosphorylated on tyrosine residues. 27 The KIT L540 and KIT K563 abnormalities of JM may be more easily dimerized and autophosphorylated than KIT WT between 0 and 1.0 ng/ml SCF. This phenomenon may result in a tiny change in the structure of the KIT molecule which causes CML cells to undergo greater proliferation and culminates in shorter survival of CML patients.
Overall, the present analysis found that these c-kit mutations do not greatly affect the pathogenesis of CML, although the presence of these mutations resulted in clinical heterogeneity of the blood and a poorer prognosis for CML patients bearing a mutation vs CML patients with normal c-kit. The poor prognosis is probably due to the higher proliferationinducing activities of 564
Leu-KIT than WT- KIT between 0 and 1.0 ng/ml SCF. The serum SCF concentration in our CML patients was between 0.5 and 1.5 ng/ml (preliminary data). Thus, CML blasts exposed to SCF concentrations between 0.5 and 1.5 ng/ml possibly undergo greater phosphorylation and proliferation. Although our findings do not fully explain the mechanisms by which 564
Leu-KIT lead to clinical heterogeneity of CML, a small functional difference from KIT WT is thought to be one cause of differences in the prognosis and the phenotype of leukocytosis in CML.
